Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Apr 16, 2018 · 10-K · 106 days after period end · 0001493152-18-005248
| Metric | Q4 2017 | Q4 2016 | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | — | — |
| Net Income | -$633.86K | -$234.34K | -$362.77K | -$1.54M |
| EPS Diluted | -$0.02 | -$0.01 | — | — |
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2017 · filed Apr 16, 2018 · 106 d after period end
